Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: billkirn who wrote (5632)	11/3/1998 5:06:00 PM
From: Steve Fancy	Respond to of 6136

Bill, I think you're right. It'll come. I'm anxious in that some naked puts I sold come due this month. I have 40's and 45's. Would be thrilled and relieved to see the 40's expire worthless. sf

To: billkirn who wrote (5632)	11/3/1998 5:12:00 PM
From: Steve Fancy	Read Replies (1) \| Respond to of 6136

Oh, and here's a story I've been carting around in my clipboard on TRMS. Other than the fact that it's a year or two away, does anyone have an opinion on T-20? Thanks, sf ========================= Trimeris CEO: T-20 Drug Fights Drug-Resistant AIDS Strains NEW YORK (Dow Jones)--Trimeris Inc.'s (TRMS) T-20 anti-HIV drug works against resistant strains of the HIV virus, which causes AIDS, according to Dr. Ross Johnson, the company's chief executive. "This drug works against the resistant viruses, that is the viruses that are already mutated to currently existing drugs," Johnson said in an interview on CNBC Tuesday. "One of the first uses that we'll look at in this class of drugs is in people failing current therapy, or multi-drug resistance," Johnson said. He explained that unlike other AIDS therapies, the T-20 drug process acts outside the cell, on the level of the virus itself. Despite positive findings for the drug in a Phase I/II clinical trial, there is still more work to be done, Johnson said. "I think in this field you have to assume that the virus is going to become resistant to almost any class of drugs," he said. "What this gives us is another weapon in the armament to fight this disease in a different mechanism, so three or four of these mechanisms working together will fool the virus more than just two or three." Johnson said Trimeris is in the middle of a 78-patient trial to determine dosage and administration method. "At the end of December or early January, based on those results, we will begin the work necessary to run a pivotal or Phase III trial, which will last about a year and a half or two years, and that will be the basis for hopefully approval," Johnson said. - By Victor Ozols; 201-938-5394